The mission of the Berlin Institute of Health at Charité (BIH) is medical translation: transferring biomedical research findings into novel approaches to personalized prediction, prevention, diagnostics and therapies and, conversely, using clinical observations to develop new research ideas. The aim is to deliver relevant medical benefits to patients and the population at large. The BIH was founded in 2013 and is funded 90 percent by the Federal Ministry of Education and Research (BMBF) and 10 percent by the State of Berlin. Since 2021 the BIH has been integrated into Charité as its so-called third pillar.
The BIH is looking from the 01.11.2023 temporarily for a
The research group Model Systems for Regenerative Therapies leverages interdisciplinary approaches to translate mechanistic findings from pre-clinical model systems towards regenerative therapies, within the musculoskeletal field. Fibrosis is the result of failed tissue regeneration and is a highly dynamic process. To move towards an improved understanding regarding failed tissue regeneration, we are creative in the design of our biomedical research projects and dedicated to exploring the unknown. The passionate research group values diversity in background and experience and strongly believe that diversity drives creativity and innovation. The research group is fully embedded within The BIH Berlin Center for Regenerative Therapies (BCRT). BCRT is a translational research focus, which pursues the rapid implementation of new research results in the field of regenerative medicine in clinical applications and products.
Fibrosis is a dynamic process and the result of dysregulated cell communication. This leads to the generation of non-functional extracellular matrix. When highly progressive, this can cause significant tissue or organ contraction and subsequent malfunction. While the functional outcome of fibrosis is well understood, the underlying cause for the initiation and progression is still largely unknown. Organ-on-a-chip technology allows the study of human cells and tissues under biophysiological and dynamic settings. However, the design of the in vitro platform, the microenvironment, as well as cells and tissues of choice are crucial for the predictive outcome.
This is a new research group and the task associated with this position is related to the build-up project of the biobanking and characterization procedures. Based on documented frequency the patient groups are seen in the clinic, it is estimated that it will take three years to process the required 100 samples and to perform the subsequent processing and characterization. The main tasks will be:
For technical queries regarding the job advertisement, please contact Ms Prof. Dr. Johanna Bolander (mail: email@example.com).
Please submit your application via the BIH Career Portal by 29.09.2023, quoting the reference number BIH-55.23.
Note: If you have a foreign university degree, please note that it may be necessary to obtain a certificate from the ZAB. You can find more information at: https://www.kmk.org/zab/central-office-for-foreign-education.html
For those born after 1970, proof of measles immunity / measles vaccination is required.
BIH strongly encourages qualified women to apply. Applications from people with a migration background who meet the hiring requirements are expressly encouraged. Applicants with severe disabilities and those of equal status will be given preferential consideration in the event of equal suitability.
You can find more information about BIH at: